Long-Term Effects on Medical Costs of Improving Depression Outcomes in Patients With Depression and Diabetes

  1. Wayne J. Katon, MD1,
  2. Joan E. Russo, MD1,
  3. Michael Von Korff, SCD2,
  4. Elizabeth H.B. Lin, MD, MPH2,
  5. Evette Ludman, PHD2 and
  6. Paul S. Ciechanowski, MD, MPH1
  1. 1Department of Psychiatry, University of Washington School of Medicine, Seattle, Washington
  2. 2Center for Health Studies, Group Health Cooperative of Puget Sound, Seattle, Washington
  1. Corresponding author: Wayne Katon, MD, Department of Psychiatry and Behavioral Sciences, Box 356560, University of Washington School of Medicine, 1959 NE Pacific St., Seattle, WA 98195-6560. E-mail: wkaton{at}u.washington.edu

Abstract

OBJECTIVE—The purpose of this study was to examine the 5-year effects on total health care costs of the Pathways depression intervention program for patients with diabetes and comorbid depression compared with usual primary care.

RESEARCH DESIGN AND METHODS—The Pathways Study was conducted in nine primary care practices of a large HMO and enrolled 329 patients with diabetes and comorbid major depression. The current study analyzed the differences in long-term medical costs between intervention and usual care patients. Participants were randomly assigned to a nurse depression intervention (n = 164) or to usual primary care (n = 165). The intervention included education about depression, behavioral activation, and a choice of either starting with support of antidepressant medication treatment by the primary care doctor or problem-solving therapy in primary care. Interventions were provided for up to 12 months, and the main outcome measures are health costs over a 5-year period.

RESULTS—Patients in the intervention arm of the study had improved depression outcomes and trends for reduced 5-year mean total medical costs of −$3,907 (95% CI −$15,454 less to $7,640 more) compared with usual care patients. A sensitivity analysis found that these cost differences were largely explained by the patients with depression and the most severe medical comorbidity.

CONCLUSIONS—The Pathways depression collaborative care program improved depression outcomes compared with usual care with no evidence of greater long-term costs and with trends for reduced costs among the more severely medically ill patients with diabetes.

Footnotes

  • Published ahead of print at http://care.diabetesjournals.org on 10 March 2008. DOI: 10.2337/dc08-0032. Clinical trial reg. no. NCT00468676, clinicaltrials.gov.

    The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C Section 1734 solely to indicate this fact.

    • Accepted February 28, 2008.
    • Received January 4, 2008.
| Table of Contents

This Article

  1. Diabetes Care vol. 31 no. 6 1155-1159
  1. All Versions of this Article:
    1. dc08-0032v1
    2. 31/6/1155 most recent